ArticleCancer gene therapy2021

EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma.

Weimei Huang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.